-
"Top Student" LOXO-435 Among FGFR3 Inhibitors
Time of Update: 2022-01-26
LOXO-435 exhibits a broad therapeutic index in vivo [4]Preclinical data for LOXO-435Preclinical data for LOXO-435The kinase profile data in Figure 7 and subsequent data demonstrating the safety of the compound demonstrate that LOXO-435 is a potent, highly isoform-selective FGFR3 inhibitor with potency against FGFR3 gatekeeper resistance mutations; LOXO -435 can avoid the dose-limiting toxicity caused by inhibition of FGFR1 and FGFR2 - hyperphosphatemia and other adverse events of chronic intolerance .
-
In 2022, the number of innovative pharmaceutical companies landing in the capital market is expected to break through again
Time of Update: 2022-01-26
In addition, there is also an IPO application for an innovative drug company on the ChiNext Board of the Shenzhen Stock Exchange, namely Hualan Vaccine, which has also been submitted to the China Securities Regulatory Commission.
-
44 proprietary Chinese medicine applications were withdrawn from the Internet, involving nearly 20 pharmaceutical companies
Time of Update: 2022-01-26
According to the notice, 44 drug product regulatory applications were withdrawn from the Internet, all of which were proprietary Chinese medicines, involving 19 Chinese medicine companies .
-
Under the drastic "price reduction" of centralized procurement, where is the way out for pharmaceutical companies?
Time of Update: 2022-01-26
Because of the cut-off of centralized procurement, a pharmaceutical factory in North China was included in the "violation list", and In the next 9 months, they cannot participate in the national centralized drug procurement activities .
-
Enterprises need to pay attention to these five points that the centralized procurement of Chinese patent medicines in Hubei has far-reaching influence!
Time of Update: 2022-01-26
The bidding results of the centralized procurement of Chinese patent medicines of the 19-province alliance of Hubei have been announced.
The bidding results of the centralized procurement of Chinese patent medicines of the 19-province alliance of Hubei have been announced.
-
In 2022, the six major tracks of the pharmaceutical sector will have a high degree of prosperity
Time of Update: 2022-01-26
On the one hand, the global innovative drug projects in the clinical stage are accelerating, the demand for CDMO will continue to grow, and overseas orders will continue to be transferred to China, bringing huge market opportunities to domestic enterprises; on the other hand, with the API + preparations With the advancement of CDMO's integrated layout, the revenue generated by a single project is also expected to increase .
-
Junshengtai Appoints Chen Jin as Senior Vice President of Pharmacokinetics and Clinical Pharmacology
Time of Update: 2022-01-26
Chen Jin has served as clinical development director and clinical pharmacology director of Novartis Cardiovascular, Nephrology and Metabolism Business Unit and Chronic Liver Disease Business Unit, and has led the clinical development of a number of new drugs, including the adaptation of Junshengtai's main focus.
-
Another new drug in the antitumor drug market has been approved!
Time of Update: 2022-01-26
It is expected in the industry that under this background, the 3 types of generic drugs of Zoledronic acid injection of NBP Pharmaceuticals of CSPC will face very fierce market competition in the future .
-
Announcement of R&D expenses of 71 pharmaceutical companies: Yiling, Baiyunshan, China Resources Sanjiu...
Time of Update: 2022-01-26
Image source: WeChat public account "Pharmaceutical Aspects"Relevant people in the industry believe that according to the current development trend of new traditional Chinese medicines, the market size is expected to exceed one trillion yuan in 2022, and will reach 1.
-
Yangzijiang's exclusive product rises 200%!
Time of Update: 2022-01-25
com, although the frequency of patient visits has been reduced due to the impact of the epidemic in 2020, there are still more than 10 gastric medicine products with sales of more than 100 million yuan in the terminal Chinese patent medicine market of public medical institutions in China.
-
Yunnan draws a 5-year development blueprint to build China's "medicine creation" highland
Time of Update: 2022-01-25
With the release of Yunnan Province's "14th Five-Year" pharmaceutical industry development plan, it will further help the high-quality development of the pharmaceutical industry including the traditional Chinese medicine industry .
-
Merck says it will significantly increase HPV vaccine supply to China in 2022
Time of Update: 2022-01-25
On January 11, according to the Financial Associated Press, Merck said that the company's HPV vaccine supply to China is increasing year by year, and will increase significantly in 2022 .
The Chinese people have had a strong demand for HPV vaccines in recent years .
-
Lukang Pharmaceutical's Ticagrelor Tablets obtained the "Drug Registration Certificate"
Time of Update: 2022-01-25
On January 11, Lukang Pharmaceutical announced that it had received the "Drug Registration Certificate" (certificate number: 2021S01335) for Ticagrelor Tablets issued by the State Food and Drug Admini
-
List of Global mRNA Vaccine Patents
Time of Update: 2022-01-25
Source: Medicine Rubik's Cube NextPat Patent DatabaseAt present, two mRNA vaccines for the treatment of new crowns have been launched, one of which is Elasomeran (code-named mRNA-1273) developed by Moderna, which has been officially launched in Japan and Europe, and has obtained emergency use authorization in the United States.
-
CSPC's anticancer drug "Mitoxantrone Hydrochloride Liposome Injection" was approved for marketing
Time of Update: 2022-01-25
Screenshot source: CDE official websiteAccording to CSPC's earlier announcement, the drug's NDA application in China is mainly based on the results of a pivotal, single-arm, multi-center Phase 2 study designed to evaluate the lipid profile of mitoxantrone hydrochloride Efficacy and safety of body injection in the treatment of relapsed/refractory peripheral T-cell and extranodal NK/T-cell lymphoma (NKTCL) .
-
At the beginning of 2022, the attention of the pharmaceutical industry has increased, and more than 460 institutions have received surveys
Time of Update: 2022-01-25
In response to the company's research and development, Xianju Pharmaceutical stated that the company will establish product groups in various therapeutic fields through market research and positioning to find and obtain the desired potential products, so as to ensure the company's continued stability in the next 5-10 years.
-
Going overseas to develop into a pharmaceutical company is an inevitable choice, and challenges are coming
Time of Update: 2022-01-25
In recent years, with the continuous improvement of the research and development capabilities of domestic innovative pharmaceutical companies, the number of new drug license-out transactions in China has been increasing, and the transaction volume has also begun to hit new highs .
-
Happy New Year!
Time of Update: 2022-01-25
According to news on January 10, the next step is to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients .
-
The listing application of Huachun Bio/Sinopharm Dezhong Traditional Chinese Medicine Class 1 new drug, Prince Shenyue Capsule, was accepted
Time of Update: 2022-01-25
Sales of terminal nervous system Chinese patent medicines in physical pharmacies in Chinese cities (unit: 10,000 yuan)Source: Minet.
2020 China's urban physical pharmacy terminal nervous system Chinese patent medicine TOP5 productsSource: Minet.
-
2022 will be a year of accelerated reshuffle in the pharmaceutical industry
Time of Update: 2022-01-25
The industry pointed out that, especially under the normalization of centralized procurement, pharmaceutical equipment companies will accelerate their transformation towards innovation, and it is expected that small and medium-sized enterprises with weak R&D capabilities will accelerate their elimination .
